Oncocyte Begins Manufacturing Transplant Blood Test
OncoCyte, Corp. (Nasdaq: OCX), a precision diagnostics company, has announced that it has started the manufacturing process for its patented transplant technology. The test measures levels of donor derived cell-free DNA (dd-cfDNA) in the blood to check for signs of graft damage in transplant recipients. The company plans to launch an early access program for this RUO kit in late Q4 2023.
The CEO of Oncocyte, Josh Riggs, stated that their method offers distinct benefits compared to other invasive approaches. He emphasized that the test provides a simple and easy-to-use workflow, allowing researchers to perform dd-cfDNA testing in-house using droplet digital PCR. By opening access to their technology, they aim to support broader research in the transplant community.
The test can be completed within